Journal of Clinical Oncology, Vol 3, 1640-1658, Copyright © 1985 by American Society of Clinical Oncology

ARTICLES

Leukemia in breast cancer patients following adjuvant chemotherapy or postoperative radiation: the NSABP experience

B Fisher, H Rockette, ER Fisher, DL Wickerham, C Redmond and A Brown

Since 1971, 8,483 women with primary breast cancer participated in seven trials evaluating adjuvant chemotherapy. Leukemia occurred in only three of 2,068 patients treated by operation alone. The cumulative risk was 0.06% after 10 years in those free of metastases or a second primary tumor, and 0.27% in those with tumor. Thus, leukemia is not an important factor in the natural history of breast cancer. Five of 646 women receiving postoperative regional radiation developed leukemia, an overall risk of 1.39 +/- .49% at 10 years. Twenty-seven cases of leukemia (0.5%) and seven of myeloproliferative syndrome (0.1%) were recorded in 5,299 patients who received L-phenylalanine mustard (L-PAM)- containing regimens. The maximum cumulative risk of leukemia in chemotherapy recipients (leukemia of any type and myeloproliferative syndrome) was 1.68 +/- .33% at 10 years following operation. The risk excluding those with myeloproliferative syndrome was 1.29 +/- .28%. The risk of leukemia in patients free of metastases or a second primary was 1.11 +/- .30% at 10 years, and when combined with myeloproliferative syndrome, it was 1.54 +/- .36%; risks not significantly greater than observed following radiation (P = .58 and .29). No cases of leukemia were observed during the 2 years of chemotherapy and none have occurred after the seventh postoperative year. Comparisons with the surveillance, epidemiology, and end results tumor registries (SEER) data indicate an increased relative risk of acute myelogenous leukemia following postoperative regional radiation (P less than .01) and adjuvant chemotherapy (P less than .001). The findings indicate that hematologic disorders are side effects of both radiation and alkylating agents used in the adjuvant treatment of primary breast cancer. The risk of such events is lower than that reported following treatment of other solid tumors and hematologic malignancies by chemotherapy. The benefit from adjuvant chemotherapy for breast cancer exceeds the risk of leukemia. Since chemotherapy is not uniformly beneficial, efforts should be directed toward identifying responders so that only those who will benefit are exposed to the risk.
CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				G. Beadle, P. Baade, and L. Fritschi Acute myeloid leukemia after breast cancer: a population-based comparison with hematological malignancies and other cancers Ann. Onc., January 1, 2009; 20(1): 103 - 109. [Abstract] [Full Text] [PDF]

				M. Ono, T. Watanabe, C. Shimizu, N. Hiramoto, Y. Goto, K. Yonemori, T. Kouno, M. Ando, K. Tamura, N. Katsumata, et al. Therapy-Related Acute Promyelocytic Leukemia Caused by Hormonal Therapy and Radiation in a Patient with Recurrent Breast Cancer Jpn. J. Clin. Oncol., August 1, 2008; 38(8): 567 - 570. [Abstract] [Full Text] [PDF]

				C. Bastianutto, A. Mian, J. Symes, J. Mocanu, N. Alajez, G. Sleep, W. Shi, A. Keating, M. Crump, M. Gospodarowicz, et al. Local Radiotherapy Induces Homing of Hematopoietic Stem Cells to the Irradiated Bone Marrow Cancer Res., November 1, 2007; 67(21): 10112 - 10116. [Abstract] [Full Text] [PDF]

				M. Crump, D. Tu, L. Shepherd, M. Levine, V. Bramwell, and K. Pritchard Risk of Acute Leukemia Following Epirubicin-Based Adjuvant Chemotherapy: A Report From the National Cancer Institute of Canada Clinical Trials Group J. Clin. Oncol., August 15, 2003; 21(16): 3066 - 3071. [Abstract] [Full Text] [PDF]

				L. J. Worrillow, L. B. Travis, A. G. Smith, S. Rollinson, A. J. Smith, C. P. Wild, E. J. Holowaty, B. A. Kohler, T. Wiklund, E. Pukkala, et al. An Intron Splice Acceptor Polymorphism in hMSH2 and Risk of Leukemia after Treatment with Chemotherapeutic Alkylating Agents Clin. Cancer Res., August 1, 2003; 9(8): 3012 - 3020. [Abstract] [Full Text] [PDF]

				R. Arriagada and J. Gutierrez Anthracyclines: is more, better and/or more dangerous? Ann. Onc., May 1, 2003; 14(5): 663 - 665. [Full Text] [PDF]

				R. E. Smith, J. Bryant, A. DeCillis, and S. Anderson Acute Myeloid Leukemia and Myelodysplastic Syndrome After Doxorubicin-Cyclophosphamide Adjuvant Therapy for Operable Breast Cancer: The National Surgical Adjuvant Breast and Bowel Project Experience J. Clin. Oncol., April 1, 2003; 21(7): 1195 - 1204. [Abstract] [Full Text] [PDF]

				R G Ghalie, E Mauch, G Edan, H P Hartung, R E Gonsette, S Eisenmann, E Le Page, M D Butine, and D E Goodkin A study of therapy-related acute leukaemia after mitoxantrone therapy for multiple sclerosis Multiple Sclerosis, October 1, 2002; 8(5): 441 - 445. [Abstract] [PDF]

				G. K. Ellis, R. B. Livingston, J. R. Gralow, S. J. Green, and T. Thompson Dose-Dense Anthracycline-Based Chemotherapy for Node-Positive Breast Cancer J. Clin. Oncol., September 1, 2002; 20(17): 3637 - 3643. [Abstract] [Full Text] [PDF]

				L. J. Pierce Treatment Guidelines and Techniques in Delivery of Postmastectomy Radiotherapy in Management of Operable Breast Cancer J Natl Cancer Inst Monographs, December 1, 2001; 2001(30): 117 - 124. [Abstract] [Full Text] [PDF]

				J. M. Allan, C. P. Wild, S. Rollinson, E. V. Willett, A. V. Moorman, G. J. Dovey, P. L. Roddam, E. Roman, R. A. Cartwright, and G. J. Morgan Polymorphism in glutathione S-transferase P1 is associated with susceptibility to chemotherapy-induced leukemia PNAS, September 5, 2001; (2001) 191211198. [Abstract] [Full Text] [PDF]

				C. L. Shapiro and A. Recht Side Effects of Adjuvant Treatment of Breast Cancer N. Engl. J. Med., June 28, 2001; 344(26): 1997 - 2008. [Full Text] [PDF]

				A. Recht, S. B. Edge, L. J. Solin, D. S. Robinson, A. Estabrook, R. E. Fine, G. F. Fleming, S. Formenti, C. Hudis, J. J. Kirshner, et al. Postmastectomy Radiotherapy: Clinical Practice Guidelines of the American Society of Clinical Oncology J. Clin. Oncol., March 1, 2001; 19(5): 1539 - 1569. [Abstract] [Full Text] [PDF]

				G. Chaplain, C. Milan, C. Sgro, P.-M. Carli, and C. Bonithon-Kopp Increased Risk of Acute Leukemia After Adjuvant Chemotherapy for Breast Cancer: A Population-Based Study J. Clin. Oncol., August 15, 2000; 18(15): 2836 - 2842. [Abstract] [Full Text] [PDF]

				K. Benson and A. J. Hartz A Comparison of Observational Studies and Randomized, Controlled Trials N. Engl. J. Med., June 22, 2000; 342(25): 1878 - 1886. [Abstract] [Full Text] [PDF]

				M. A. Smith, L. Rubinstein, J. R. Anderson, D. Arthur, P. J. Catalano, B. Freidlin, R. Heyn, A. Khayat, M. Krailo, V. J. Land, et al. Secondary Leukemia or Myelodysplastic Syndrome After Treatment With Epipodophyllotoxins J. Clin. Oncol., February 1, 1999; 17(2): 569 - 569. [Abstract] [Full Text] [PDF]

				A. I. Neugut, E. Robinson, J. Nieves, T. Murray, and W.-Y. Tsai Poor Survival of Treatment-Related Acute Nonlymphocytic Leukemia JAMA, August 22, 1990; 264(8): 1006 - 1008. [Abstract] [PDF]

				L. J. Loescher, D. Welch-McCaffrey, S. A. Leigh, B. Hoffman, and F. L. Meyskens Jr Surviving Adult Cancers. Part 1: Physiologic Effects Ann Intern Med, September 1, 1989; 111(5): 411 - 432. [Abstract] [PDF]

				M. H. GREENE, E. L. HARRIS, D. M. GERSHENSON, G. D. MALKASIAN Jr., L. J. MELTON III, A. J. DEMBO, J. M. BENNETT, W. C. MOLONEY, and J. D. BOICE Jr. Melphalan May Be a More Potent Leukemogen than Cyclophosphamide Ann Intern Med, September 1, 1986; 105(3): 360 - 367. [Abstract] [PDF]

				J. M. Allan, C. P. Wild, S. Rollinson, E. V. Willett, A. V. Moorman, G. J. Dovey, P. L. Roddam, E. Roman, R. A. Cartwright, and G. J. Morgan Polymorphism in glutathione S-transferase P1 is associated with susceptibility to chemotherapy-induced leukemia PNAS, September 25, 2001; 98(20): 11592 - 11597. [Abstract] [Full Text] [PDF]